Atlas Trials

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

Clinical trial NCT06685289 · RECRUITING

Trial details

NCT number
NCT06685289
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Malignant Tumors
Start date
2024-11-15
Primary completion
2026-11-15
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.